BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Stock Information for BioCardia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioCardia Inc.

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.